There is a critical need for new therapeutic approaches to treat advanced stage rectal cancer, which has increased incidence in younger people and poor prognosis. Working with a multidisciplinary team, Dr. Aguilera is leading a randomized clinical trial that combines an anti-CD40 agonist immunotherapy with radiation and chemotherapy for locally advanced rectal cancer. The drug aims to activate the protein CD40 on dendritic cells which plays a critical role in generating T-cell immunity. As part of the study, Dr. Aguilera is investigating the factors that influence a patient's immune response to this combination treatment with the goal of optimizing therapy for difficult gastrointestinal cancers. If the proposed treatment is successful, it could become a new therapeutic standard that lowers the risk of metastasis, improves survival, shortens the treatment course and potentially avoids the need for surgery.

Defects in the cellular DNA repair machinery can promote cancer formation and cause cancer cells to rely on back-up DNA repair processes. These cancer cells are particularly vulnerable to drugs called PARP inhibitors, which target a DNA repair process known as homologous recombination. Dr. Chan hypothesizes that a similar treatment strategy can be used for cancers with deficiencies in DNA mismatch repair, which causes microsatellite—short, repeated sequences of DNA—instability (MSI). Microsatellite instability is found most often in certain colon, stomach, uterine and ovarian cancers. Using CRISPR screening technology, Dr. Chan discovered that cancer cells with faulty mismatch repair become dependent on a gene called WRN to survive. He is characterizing this vulnerability for MSI cancers with the goal of finding new drugs that inhibit this pathway.

Dr. Donaldson is investigating the difference between a healthy mucosal surface and a tumor-promoting surface in the gut. Bacteria in the gut associate intimately with the surface of the intestine, where they exert a constant influence on the immune system throughout an organism’s life. Studies indicate that certain gut bacteria in cancer patients reside in the mucus of the intestinal surface and may promote (or potentially inhibit) the growth of tumors, perhaps through effects on the immune system. Uncovering specific “molecular conversations” that maintain a healthy community of mucosal bacteria may lead to novel therapies to prevent the origin of colorectal cancers in addition to treating existing tumors.

Over 90% of cancer deaths are caused by metastasis, the spread of cancer cells to distant organs, where uncontrolled cancer cell growth lethally compromises organ function. Despite recent advances, current treatments fail to effectively control metastasis. Dr. Ganesh is growing colorectal cancer cells, removed from patients during surgery, as three-dimensional “organoids.” This cutting-edge technology models the complexity of human organs more accurately than cells growing in a dish. Using colorectal cancer organoids, her group is studying how cancer cells gain the ability to spread and grow outside their organ of origin. Her work is uncovering core signaling modules required for metastasis, with the goal of developing more effective treatments for patients with advanced cancers. Dr. Ganesh works under the mentorship of Joan Massague, PhD, at Memorial Sloan Kettering Cancer Center, New York.

Cancer immunotherapy mobilizes the body's own sophisticated defenses to target and kill cancer cells. Despite its enormous promise, immunotherapy is only effective in a subset of cancers in a small group of patients. Dr. Han is investigating the role of the immune system's T cells in human colorectal cancer, which has limited treatment success with immunotherapy. He is using unique tools to improve our fundamental understanding of tumor immunity and to directly test a new therapeutic approach based on his hypothesis that our bodies produce T cells capable of specifically targeting a patient's tumors. His proposed research explores a strategy to identify these T cells and use genetic engineering to enable them to realize their full potential. He anticipates his findings will be applicable to other types of cancers as well.

DNA stores the information for making all the proteins in an organism. Transfer RNA (tRNA) plays a key role in building the proteins from this blueprint. tRNA molecules recognize specific sequences (three-letter codons) and deliver the corresponding amino acids needed to make a protein. Dr. Hsu recently found that certain starvation conditions can cause some tRNAs to be modulated in colorectal cancer cells. He will study the changes in tRNA levels that occur in response to cellular starvation states. He aims to shed light on how cancer cells adapt to starvation, which potentially can lead to new therapeutic approaches to target metabolic dependencies in cancer.

Dr. Hueschen studies the motility of Apicomplexan parasites, which cause malaria, foodborne illness (toxoplasmosis) and infections in immunocompromised cancer patients. These parasites move through the human body using a mechanism called "gliding" to migrate over host cells and through the surrounding extracellular matrix. Dr. Hueschen's goal is to understand how molecules inside the parasite are organized, coordinated and regulated to produce forces that direct movement. This research has the potential to aid in the development of therapies to prevent opportunistic infections.

Dr. Kacsoh is studying how social environment can affect disease initiation or progression. Empirical evidence suggests that extreme social environments—such as overcrowding or isolation—can induce or accelerate disease states such as cancer, but little is known about the underlying biology. Dr. Kacsoh proposes to dissect the molecular processes underlying disease progression as a function of social structure by using the very social model organism, the ant species Camponotus floridanus, and by generating a colorectal-like tumor model in these ants. Studies of model organisms with conserved cancer pathways may provide clues to the links between social environment and disease.

Therapies that directly target cancer-promoting oncoproteins have revolutionized the treatment of cancer. Cancers, however, are primed to adapt and evolve in the presence of treatment, resulting in an ability to resume growth despite the presence of therapy. Utilizing cutting-edge new techniques that allow the determination of genetic alterations in single cancer cells, Piro aims to understand the principles that govern the evolution of resistance during therapy and identify novel therapeutic interventions that halt this process. His specific focus will be on improving the efficacy of KRAS inhibition for treatment of lung and colorectal cancers.

Dr. Moy is focusing on key genes and pathways that control metastasis of colorectal cancer to the liver. Dr. Moy’s research could potentially lead to new treatment strategies that can block or delay metastatic progression of colorectal cancer and other gastrointestinal malignancies. Understanding this process at the molecular level has the potential to impact patient survival.